Cellular therapies company Actinium Pharmaceuticals Inc (NYSE American:ATNM) reported on Tuesday the election of Mamata Gokhale, PhD, RAC as vice president, global head of its Regulatory Affairs.
In the senior position, Dr Gokhale will develop and implement a comprehensive clinical regulatory strategy across the company's portfolio of ARC or Antibody Radiation-Conjugate product candidates for targeted conditioning, including] the pivotal Phase 3 trial for its lead candidate Iomab-B, therapeutic and combination trials of Actimab-A, as well as potential next-generation ARC's resulting from its AWE or Antibody Warhead Enabling technology platform.
Previously, Dr Gokhale has worked at biotechnology and pharma companies including Amgen, Watson Pharma, Neumedicines Inc as well as in global Contract Research Organisations including Voisin Consulting Life Sciences and Paraxel International.
Earlier in her career, Dr Gokhale was part of the US Food and Drug Administration for over 20 years in regulatory positions of increasing responsibility.
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA
European Commission approves Camurus' once-monthly octreotide treatment for acromegaly